
AstraZeneca
OrganizationHeard in 65 episodes across 22 shows since Oct 2025
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in Cambridge, England. It discovers, develops, manufactures, and commercializes medicines across areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation; the podcast references primarily concern its role as a major pharmaceutical competitor, drug-development partner or licensor, and potential acquirer.
Episodes
This week
Expert statements
Share of the conversation
Mentions of AstraZeneca per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 31 | 0.01‰ | 1 |
| Sep 8 | 0.02‰ | 2 |
| Sep 13 | 0.03‰ | 1 |
| Sep 14 | 0.04‰ | 1 |
| Sep 29 | 0.06‰ | 7 |
| Sep 30 | 0.07‰ | 1 |
| Oct 5 | 0.08‰ | 1 |
| Oct 13 | 0.02‰ | 2 |
| Oct 27 | 0.02‰ | 2 |
| Oct 29 | 0.03‰ | 1 |
| Oct 30 | 0.04‰ | 2 |
| Oct 31 | 0.05‰ | 1 |
| Nov 2 | 0.06‰ | 1 |
| Nov 6 | 0.03‰ | 2 |
| Nov 9 | 0.02‰ | 1 |
| Nov 16 | 0.02‰ | 2 |
| Nov 17 | 0.02‰ | 1 |
| Nov 20 | 0.05‰ | 3 |
Email alert
Email me when AstraZeneca comes up on a podcast
One email a week at most, with the new episodes that mention AstraZeneca. Free, no account needed, unsubscribe in one click.
What experts have said about AstraZeneca
18 statements · 8 positive · 8 negative · 2 neutral
Investors should avoid AstraZeneca.
“I am not going to put my money on AstraZeneca.”
Open the episode · 'Mad Money w/ Jim Cramer 9/8/26Listen at 39:21
AstraZeneca shares remain depressed since July
“AstraZeneca shares are pretty depressed since July”
Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx SurgesListen at 1:26
AstraZeneca shares may be experiencing a modest rebound
“it could just be rebounding a little bit”
Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx SurgesListen at 1:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
65 episodes featuring AstraZeneca, newest first
- Nov 20, 2026
UK regulators test faster, more flexible biotech pathwaysBioCentury This WeekNov 20, 2026 - Nov 20, 2026
Biotech weighs AI disruption against a stronger 2027 deal cycleBiotech HangoutNov 20, 2026 - Nov 20, 2026
FDA leadership falters as China biotech reshapes drug competitionThe Readout LoudNov 20, 2026 - Nov 17, 2026
Chip controls test Trump’s Asia strategyWSJ What’s NewsNov 17, 2026 - Nov 16, 2026
Candel bets on in situ immunization for prostate cancerBusiness Of BiotechNov 16, 2026 - Nov 9, 2026
Biotech investors weigh obesity, RAS drugs and Moderna catalystsBreaking BiotechNov 9, 2026